Sign Up Today and Learn More About GlycoEra Stock
Invest in or calculate the value of your shares in GlycoEra or other pre-IPO companies through EquityZen's platform.
GlycoEra Stock
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
About GlycoEra Stock
Founded
2020
Industries
Software, Artificial Intelligence, Data and Analytics
GlycoEra Press Mentions
Stay in the know about the latest news on GlycoEra
GlycoEra Secures USD 130 Million in Series B Financing Led by Novo Holdings and LifeArc Ventures
globallegalchronicle • Jun 04, 2025
Glycoera raises a $130M series B to advance GE-8820
bioworld • Jun 03, 2025
GlycoEra raises USD 130 Million Series B to advance targeted autoimmune therapies
venturelab • May 29, 2025
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
biospace • May 28, 2025
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
globenewswire • May 27, 2025
GlycoEra Management
Leadership team at GlycoEra
Board of Directors
Amir Faridmoayer
President and CEO
Ganesh Venkataraman Kaundinya
Join now and verify your accreditation status to gain access to:
- GlycoEra Current Valuation
- GlycoEra Stock Price
- GlycoEra Management
- Available deals in GlycoEra and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- GlycoEra Cap Table and Funding History by Share Class and Liquidity Preferences
- GlycoEra Revenue and Financials
- GlycoEra Highlights
- GlycoEra Business Model
- GlycoEra Risk Factors
- GlycoEra Research Report from SACRA Research
Trading GlycoEra Stock
How to invest in GlycoEra stock?
Accredited investors can buy pre-IPO stock in companies like GlycoEra through EquityZen funds. These investments are made available by existing GlycoEra shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell GlycoEra stock?
Shareholders can sell their GlycoEra stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."